GlassScriptPhysician profile
Shannon Trantham
NPI 1255969580
$839.02
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $839.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $140.38 | 2021 | |
| Abbvie INC. | $84.38 | 2021 | |
| Astellas Pharma US INC | $82.46 | 2021 | |
| Amgen INC. | $73.83 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $66.50 | 2021 | |
| Pfizer INC. | $64.61 | 2021 | |
| Esperion Therapeutics, INC. | $44.51 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.70 | 2021 | |
| Novo Nordisk INC | $27.73 | 2021 | |
| Eisai INC. | $27.47 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.49 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.59 | 2021 | |
| Sanofi-Aventis U.S. LLC | $18.83 | 2021 | |
| Janssen Pharmaceuticals, INC | $17.70 | 2021 | |
| Dexcom, INC. | $16.85 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $15.60 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.19 | 2021 | |
| Orexo US, INC. | $13.99 | 2021 | |
| Biodelivery Sciences International, INC. | $13.75 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $12.81 | 2021 | |
| Glaxosmithkline, LLC. | $12.65 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Trantham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.